

REMARKS

Claims 1-12 are pending.

The amendments are fully supported by the original disclosure and, thus, no new matter is added by their entry. If the Examiner should disagree, however, it is respectfully requested that the challenged limitation be pointed out with particularity in the next Action so support may be cited in response.

The attached paper and computer readable forms of the Sequence Listing do not add new matter, and their contents are the same. The entry <223> of SEQ ID NOS:36-44 is corrected to state that the amino acid at the indicated position(s) may be mutated, because those sequences are not modified. Support for this correction can be found in claims 2-3 and 6-7. It is respectfully submitted that the attached complies with 37 CFR § 1.821 et seq. Otherwise, prompt notice of any defects in the Sequence Listing is earnestly solicited and additional time is requested to comply.

The enclosed Form PTO-1449 lists U.S. patent documents that correspond to foreign patent documents already made of record. As provided by 37 CFR §§ 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all possible material information. Furthermore, no inference should be made that the cited references are prior art merely because they have been submitted for consideration. Consideration of the foregoing and enclosures, as well as the return of a copy of the Form PTO-1449 with the Examiner's initials per M.P.E.P. § 609, are earnestly solicited.

Applicants earnestly solicit an early and favorable examination on the merits. The Examiner is invited to contact the undersigned if any further information is required.

Respectfully submitted,

NIXON & VANDERHYTE P.C.

By: 

Gary B. Tanigawa
Reg. No. 43,180

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100